n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide and Ovarian Neoplasms

n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide has been researched along with Ovarian Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Gruet, M; Keun, HC; Lorentzen, MP; Ma, Y; McKinney, F; McNeish, I; Nijhuis, A; Shepherd, MR; Spear, S; Wickremesinghe, C; Xu, Y	1

Other Studies

1 other study(ies) available for n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide and Ovarian Neoplasms

Article	Year
Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma. Cell reports, 2023, 10-31, Volume: 42, Issue:10 Topics: Animals; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Female; Humans; Mice; Mutation; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors; RNA; RNA Splicing; RNA Splicing Factors	2023

Article

Year

Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma.

Cell reports, 2023, 10-31, Volume: 42, Issue:10

Topics: Animals; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Female; Humans; Mice; Mutation; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors; RNA; RNA Splicing; RNA Splicing Factors

2023